ライフサイエンスコーパス: prostaglandin D2

1 peT(H)2 but not cT(H)2 cells produced prostaglandin D2.

2 vage fluid (BALF) contain elevated levels of prostaglandin D2.

3 alpha, prostaglandin I2, thromboxane A2, and prostaglandin D2.

4 ase of the mast cell mediators histamine and prostaglandin D2.

5 pase D, which can increase the production of prostaglandin D2.

6 erbation was associated with reduced exudate prostaglandin D2 and 15deoxy delta(12-14)prostaglandin J

7 ng, resulting in the synthesis of 15R-methyl prostaglandin D2 and allows rapid access to other prosta

8 results from GPR109A-mediated production of prostaglandin D2 and E2 in Langerhans' cells which act o

9 Median sputum prostaglandin D2 and prostaglandin E2 concentrations wer

10 tamine, cysteinyl-leukotrienes, prostanoids (prostaglandin D2 and prostaglandin E2), and interleukin-

11 T cells highly express Cox-2 and synthesize prostaglandin D2 and related prostaglandins that are PPA

12 nd release of arachidonate, the precursor of prostaglandin D2 and the vasodilator responsible for the

13 r prostanoids: prostacyclin, thromboxane A2, prostaglandin D2, and 12-hydroxyheptadecatrienoic acid.

14 In contrast, levels of prostaglandin D2, and 15deoxy delta(12-14)prostaglandin

15 Bronchoalveolar lavage fluid cells, prostaglandin D2, and cysteinyl leukotrienes from hyperv

16 ls, along with increased production of IL-5, prostaglandin D2, and eosinophil and T-helper type 2 cel

17 Release of beta-hexosaminidase, prostaglandin D2, and GM-CSF and changes in reactive oxy

18 ors (histamine, serotonin, leukotriene C(4), prostaglandin D2, and mouse mast cell protease 1) were q

19 enase-activating protein, 15-lipoxygenase-1, prostaglandin D2, and proinflammatory cytokines.

20 tabolites of prostacyclin, prostaglandin E2, prostaglandin D2, and thromboxane A2 were also reduced.

21 ocation, showing increases in metabolites of prostaglandin D2, cysteinyl leukotrienes, and isoprostan

22 AGN 211377 antagonizes prostanoid prostaglandin D2 (DP)1, DP2, prostaglandin E2 (EP)1, EP4

23 We have reported that bioactive prostaglandin D2/E2-like compounds, termed D2/E2-isopros

24 on pathways mediating the anti-lipolytic and prostaglandin D2/flushing pathways are distinct and that

25 ect appears to be mediated by the release of prostaglandin D2 from Langerhans cells in the skin.

26 nase-2 to give rise to the anti-inflammatory prostaglandin D2-glycerol ester (PGD2-G).

27 er than twice the upper limit of normal) and prostaglandin D2 (>3.4 times the upper limit of normal)

28 Prostaglandin D2 has been established as promoting the r

29 Prostaglandin D2 has been shown to have growth inhibitor

30 Prostaglandin D2 levels were measured with ELISA.

31 been previously reported that in addition to prostaglandin D2, mast cells produce other eicosanoids,

32 induced a dose-related reduction in ex vivo prostaglandin D2-mediated eosinophil shape change.

33 Although it has been reported that prostaglandin D2 mediates allergic inflammation via its

34 Basal prostaglandin D2 metabolite (PGD-M; 13.6 +/- 2.7 vs 7.0

35 urring compounds such as fatty acids and the prostaglandin D2 metabolite 15-deoxy-delta prostaglandin

36 strogen treatment induced the formation of a prostaglandin D2 metabolite that activated duck PPARgamm

37 suggest that PPAR-gamma and locally produced prostaglandin D2 metabolites are involved in the regulat

38 Prostaglandin D2 metabolites have not yet been identifie

39 selective DP2 agonist 13, 14-dihydro-15-keto prostaglandin D2 on epithelial cell migration and differ

40 04418948, but not by the antagonists of EP4, prostaglandin D2, or prostacyclin receptors.

41 set of patients with AERD is associated with prostaglandin D2 overproduction.

42 Prostaglandin D2 (PGD2 ) plays an important role in alle

43 Prostaglandin D2 (PGD2) acting at the CRTH2 receptor (ch

44 Prostaglandin D2 (PGD2) and cysteinyl leukotrienes (cysL

45 Also, levels of prostaglandin D2 (PGD2) and lipoxin A4 (LXA4) in patient

46 Arachidonic acid (AA) and prostaglandin D2 (PGD2) as well as some of the lysophosp

47 Effects of common pesticides on prostaglandin D2 (PGD2) inhibition in SC5 mouse Sertoli

48 Prostaglandin D2 (PGD2) is an extensively studied sleep-

49 ks provide evidence of the importance of the prostaglandin D2 (PGD2) metabolic pathway in inflammator

50 n-type prostaglandin D synthase (L-PGDS) and prostaglandin D2 (PGD2) metabolites produced by normal p

51 In contrast, the time course of prostaglandin D2 (PGD2) or 9 alpha, 11 beta PGF2 (11 bet

52 a,beta-unsaturated ene acid 1-E to give 2, a prostaglandin D2 (PGD2) receptor antagonist.

53 We show in this paper that lipocalin-type prostaglandin D2 (PGD2) synthase (L-PGDS) interacts intr

54 Prostaglandin D2 (PGD2) synthesis in activated mast cell

55 monly used in the European Union to suppress prostaglandin D2 (PGD2) synthesis.

56 motaxis of inflammatory cells in response to prostaglandin D2 (PGD2), is hypothesized to play a role

57 niacin provokes Langerhans cells to produce prostaglandin D2 (PGD2), stimulating vascular DP1 recept

58 Furthermore, we also show how prostaglandin D2 (PGD2), which is upregulated in balding

59 activation, including abundant production of prostaglandin D2 (PGD2).

60 a), prostaglandin F(2alpha) (PGF2alpha), and prostaglandin D2 (PGD2).

61 line, induces the synthesis and secretion of prostaglandin D2 (PGD2).

62 mphopoietin [TSLP]) and mast cell mediators (prostaglandin D2 [PGD2]) are critical activators of ILC2

63 ible and competitive with the native agonist prostaglandin D2(PGD2).

64 ed in combination with niacin to abolish the prostaglandin D2-(PGD2)-induced flushing.

65 amster ovary cells and permits chemokine and prostaglandin D2 production by LAD2 cells, a human mast

66 esulted in over 50% decrease in KLA-elicited prostaglandin D2 production.

67 13, 14-Dihydro-15-keto prostaglandin D2 promoted epithelial cell migration and

68 excretion of the major urinary metabolite of prostaglandin D2 (r = 0.98) and Ntau-methylhistamine (r

69 circulated human CD4+ T cells expressing the prostaglandin D2 receptor (CRTH2) are TH2 central memory

70 Laropiprant is a highly selective prostaglandin D2 receptor 1 antagonist that mitigates ni

71 that fevipiprant (QAW039), an antagonist of prostaglandin D2 receptor 2, might reduce eosinophilic a

72 histocompatibility complex type II, and the prostaglandin D2 receptor CD294, all normally associated

73 gic rhinitis (SAR) is partly mediated by the prostaglandin D2 receptor chemoattractant receptor homol

74 mokine receptor CCR5 (Th1/Tc1-specific), and prostaglandin D2 receptor CRTH2 (Th2/Tc2-specific).

75 identified prostaglandin E2 receptor EP2 and prostaglandin D2 receptor DP as responsive to OxPAPC.

76 econd intron of the thromboxane A2 receptor, prostaglandin D2 receptor, prostaglandin I2 receptor, an

77 d, compound 1 (AGN 211377), that antagonizes prostaglandin D2 receptors (DPs) DP1 (49) and DP2 (558),

78 ect the functional consequences of decreased prostaglandin D2 release and the therapeutic benefit of

79 Lipocalin-type prostaglandin D2 synthase (L-PGDS) has recently been lin

80 dehydrogenase 2 (RALDH2) and lipocalin-type prostaglandin D2 synthase (LPGDS), which, respectively,

81 The levels of WIHN, lipocalin-type prostaglandin D2 synthase (Ptgds), and its product PGD2

82 In contrast, prostaglandin D2 synthase declined during late torpor an

83 matrix metalloproteinase 11, integrin beta2, prostaglandin D2 synthase, and interleukin-1 receptor an

84 tatin A, Charcot-Leydon crystal protein, and prostaglandin D2 synthase, implying their broader roles

85 betaTP, also known as prostaglandin D2 synthase, is a lipocalin secreted from

86 nhibitors, galectins, osteonectin/SPARC, and prostaglandin D2 synthase.

87 ibited antigen-induced PMC degranulation and prostaglandin D2 synthesis in vitro.

88 andin-J2 (delta 12-PG J2) is a derivative of prostaglandin D2 that has been shown to have similar inh

89 Conversion of prostaglandin D2 to a metabolite was induced by estradio

90 andin J2, whereas under the same conditions, prostaglandin D2 was not effective.

91 It is the second receptor for Prostaglandin D2, whose activation leads to chemotaxis a